Open Access. Powered by Scholars. Published by Universities.®
Biomedical Engineering and Bioengineering Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Biomedical Engineering and Bioengineering
Toward Development Of Continuous Bioprocesses: Comparison Of Fed-Batch And Perfusion Upstream Production Processes In Early Development, Jean Mclarty, Daryl Powers, Christine Hamel, Betsy Simons, Ken Karey
Toward Development Of Continuous Bioprocesses: Comparison Of Fed-Batch And Perfusion Upstream Production Processes In Early Development, Jean Mclarty, Daryl Powers, Christine Hamel, Betsy Simons, Ken Karey
Cell Culture Engineering XV
Continuous Processing is an exciting development in the field of bioprocessing. The potential for quick response to market demands, decrease in infrastructure, increased flexibility and consistent product quality has resulted in a growing interest in Continuous Processing for production of all types of protein drugs (high or low volume, stable or unstable). Sanofi is developing a novel Integrated Continuous Manufacturing platform for biologics that utilizes an upstream perfusion process. While cell culture perfusion processes offer substantial benefits for commercial biologics production, implementation may present challenges in early development, where speed to first in man studies is critical. Here we present …
Integrated Strategies For The Production, Maturation And Storage Of Functional Cardiomyocytes Derived From Human Pluripotent Stem Cells, Claudia Correia, Paula Alves
Integrated Strategies For The Production, Maturation And Storage Of Functional Cardiomyocytes Derived From Human Pluripotent Stem Cells, Claudia Correia, Paula Alves
Cell Culture Engineering XV
The production of cardiomyocytes (CM) from human pluripotent stem cells (hPSC) holds great promise for cardiotoxicity drug testing, disease modeling and cardiac regeneration [1]. However, the complex nets of signalling pathways involved in cardiomyogenesis compromises the effectiveness of the existing differentiation protocols to reproducibly produce high-quality CM from hPSC (hPSC-CM). Produced hPSC-CM are immature compared with adult CMs, express typical fetal cardiac genes, have immature electrophysiological properties and use glucose as major energy source [2]. The applicability of hPSC-CM in the clinic/industry is also dependent on the development of efficient methods for worldwide shipment of these cells. In this study …